The Beijing Angle Closure Progression Study

NCT05563623 | Recruiting

• 1 other identifier: PekingUPHOphthalmology001
• Study Type: observational
• Target: 825
• Locations: 1 country
• Sites: 1

Brief Summary

The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.

Conditions

Angle-Closure Glaucoma

Outcome Measures

Primary Outcomes (2)

• the progression rate 1

  the rate of acute angle closureanterior synechiae

  6 months

• the progression rate 2

  the proportion of eyes developing peripheral

  6 months

Study Arms (2)

progression group

non-progression group

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with primary angle-closure suspect who agree to take part in this trial were given a comprehensive baseline examination and who decline will be asked for a reason. Verbal and written informed consent was obtained from every patient. A comprehensive baseline examination will be done for every enrolled subjects. Patients are monitored for 5 years. All examinations that may be related to subjective judgment and manipulation, i.e. Goldmann applanation (GAT), ultrasound biomicroscopy (UBM), gonioscopy, are performed by experienced examiner.

You may qualify if:

• "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field.
• Able to provide informed consent

You may not qualify if:

• Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy).
• Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty
• Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy.
• Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor.
• Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer.
• Severe eye diseases, such as cataract, macular disease, and retinal detachment.

Sponsors & Collaborators

• Peking University People's Hospital: lead

Study Sites (1)

Peking University People's Hospital

Beijing, Beeijing, 100044, China

RECRUITING

MeSH Terms

Conditions

Glaucoma, Angle-Closure

Condition Hierarchy (Ancestors)

Glaucoma; Ocular Hypertension; Eye Diseases

Central Study Contacts

Huijuan Wu, M.D. Ph.D.

CONTACT

8613811293109; dr_wuhuijuan@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Leader of Glaucoma Group of Ophthalmology Department, Peking University People's Hospital

Study Record Dates

• First Submitted: September 26, 2022
• First Posted: October 3, 2022
• Study Start: August 4, 2022
• Primary Completion: December 31, 2025
• Study Completion (Estimated): December 31, 2030
• Last Updated: October 3, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)